With other major players like Sun Pharma and Dr Reddy's also set to launch, the entry of Natco's ₹1,290 per month vial signals a significant shift in affordability.

Eris launch coincides with a parallel entry by Natco Pharma, which will also bring its semaglutide injections to market on the first day of patent expiry tomorrow ...

Novo Nordisk is expected to lose the patent in 10 more countries, including Brazil, China, South Africa, Turkey, and Canada, by the end of 2026.

NATCO Pharma Limited announces launch of Semaglutide Injection (multi dose vials) in the India market tomorrow on Day 1 of ...

Natco Pharma will launch its Semaglutide injection (multi dose vials) in the domestic market on Saturday. It will be available tomorrow, day 1 of patent expiry, the Hyderabad-based generic drugmaker ...

Natco Pharma plans to launch a semaglutide injection, the key ingredient in Novo Nordisk’s Ozempic and Wegovy, at a starting ...

The company said it is introducing the diabetes and weight management medication in multi-dose vial formats at highly accessible pricing starting at ₹1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml ...

Eris & Natco launch generic Semaglutide (Ozempic, Wegovy) in India after patent expiry. Affordable diabetes & weight management options available.

Natco Pharma said the multi-dose vial format is priced around 70% lower than pen devices and nearly 90% cheaper than the innovator product, aimed at improving patient access and long-term treatment ...

Multi-dose vials will be launched at MRP of Rs 1,290 per month for 2 mg/1.5ml & 4mg/3ml and MRP of Rs 1,750 for 8mg/3ml, said Natco Pharma ...

Natco Pharma launches Semaglutide injection in India for type-2 diabetes, with pricing details and brand names announced.